Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Reuters: Greece Plans to Impose 15% Capital Gains Tax on Cryptocurrency

Reuters: Greece Plans to Impose 15% Capital Gains Tax on Cryptocurrency

ForesightNewsForesightNews2026/06/05 13:20
Show original

Foresight News reports, citing Reuters, that two informed Greek government officials have revealed the Ministry of Finance is preparing legislation to impose a 15% capital gains tax on cryptocurrencies, which is expected to be submitted to parliament for review in the coming months. According to the plan, each taxpayer’s first 500 euros of gains will be tax-exempt; individual mining activities will not be taxed, but mining companies registered as enterprises will be subject to taxation. Currently, Greece lacks a comprehensive tax framework for cryptocurrencies, and the tax rates across EU countries vary widely, ranging from 8% in Cyprus to 30% in France. Officials stated that since most Greek investors use overseas platforms, it is presently difficult to estimate the size of the country's crypto market, and no specific tax revenue forecast is yet available.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage